Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • David M Charytan
  • Scott D Solomon
  • Peter Ivanovich
  • Giuseppe Remuzzi
  • Mark E Cooper
  • Janet B McGill
  • Hans-Henrik Parving
  • Patrick Parfrey
  • Ajay K Singh
  • Emmanuel A Burdmann
  • Andrew S Levey
  • Dick de Zeeuw
  • Kai-Uwe Eckardt
  • John J V McMurray
  • Brian Claggett
  • Eldrin F Lewis
  • Marc A Pfeffer
Vis graf over relationer

BACKGROUND: How cardiovascular (CV) events affect progression to end-stage renal disease (ESRD), particularly in the setting of type 2 diabetes, remains uncertain.

STUDY DESIGN: Observational study.

SETTING & PARTICIPANTS: 4,022 patients with type 2 diabetes, anemia, and chronic kidney disease from the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

PREDICTOR: Postrandomization CV events.

OUTCOMES: ESRD (defined as initiation of dialysis for >30 days, kidney transplantation, or refusal or nonavailability of renal replacement therapy) and post-ESRD mortality within 30 days and during overall follow-up after an intercurrent CV event.

LIMITATIONS: Population limited to clinical trial participants with diabetes and anemia.

RESULTS: 155 of 652 (23.8%) ESRD cases occurred after an intercurrent CV event; 110 (16.9%) cases followed heart failure, 28 (4.3%) followed myocardial infarction, 12 (1.84%) followed stroke, and 5 (0.77%) followed multiple CV events. ESRD rate was higher within 30 days in individuals with an intercurrent CV event compared with those without an intercurrent event (HR, 22.2; 95% CI, 17.0-29.0). Compared to no intercurrent CV events, relative risks for ESRD were higher after the occurrence of heart failure overall (HR, 3.4; 95% CI, 2.7-4.2) and at 30 days (HR, 20.1; 95% CI, 14.5-27.9) than after myocardial infarction or stroke (P<0.001). Compared with individuals without pre-ESRD events, those with ESRD following intercurrent CV events were older, were more likely to have prior CV disease, and had higher (24.4 vs 23.1mL/min/1.73m2; P=0.01) baseline estimated glomerular filtration rates (eGFRs) and higher eGFRs at last measurement before ESRD (18.6 vs 15.2mL/min/1.73m2; P<0.001), whereas race, sex, and medication use were similar. Post-ESRD mortality was similar (P=0.3) with and without preceding CV events.

CONCLUSIONS: Most ESRD cases occurred in individuals without intercurrent CV events who had lower eGFRs than individuals with intercurrent CV events, but similar post-ESRD mortality. Nevertheless, intercurrent CV events, particularly heart failure, are strongly associated with risk for ESRD. These findings underscore the need for kidney-specific therapies in addition to treatment of CV risk factors to lower ESRD incidence in diabetes.

TidsskriftAmerican journal of kidney diseases : the official journal of the National Kidney Foundation
Udgave nummer4
Sider (fra-til)522-531
Antal sider10
StatusUdgivet - okt. 2017

ID: 52659510